ConductScience.org, home

Paper72276

Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder.

Brackmann HH and 1 other. Lancet, 1977. Cited by 231 papers, by iCite.

Cite this record

ConductScience Library. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Papers, record 72276. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/72276

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder.
PubMed
Journal
Lancet
PubMed
Year
1977
PubMed
Publication types
Case Reports, Letter
PubMed
Citations, by iCite
231
iCite
Relative citation ratio, by iCite
5.78
iCite
Revised in PubMed
2019-06-10
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Brackmann HHH H
2Gormsen JJ

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Factor VIIMajor topic
Hemophilia AMajor topic
Adult
Factor IX
Factor VIII
Hemorrhage
Humans
Infusions, Parenteral
Male
Time Factors

Source PubMed

Download CSV of topics

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 231 citations.

PMIDTitleJournalYearIn PapersSource
42307860Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.BioDrugs2026https://conductscience.org/library/papers/42307860PubMed
39583653Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses.Ther Adv Hematol2024https://conductscience.org/library/papers/39583653PubMed
36915910Adeno-associated virus-vectored delivery of HIV biologics: the promise of a "single-shot" functional cure for HIV infection.J Virus Erad2023https://conductscience.org/library/papers/36915910PubMed
36882773Assessing the value of bypassing agent therapy used prophylactic versus on-demand, during immune tolerance induction for treatment of inhibitors: a retrospective chart review.Orphanet J Rare Dis2023https://conductscience.org/library/papers/36882773PubMed
36377659Until programmed death do us tolerant.J Clin Invest2022https://conductscience.org/library/papers/36377659PubMed
36107620Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.J Clin Invest2022https://conductscience.org/library/papers/36107620PubMed
35793465Immune complications and their management in inherited and acquired bleeding disorders.Blood2022https://conductscience.org/library/papers/35793465PubMed
34168126Haemophilia.Nat Rev Dis Primers2021https://conductscience.org/library/papers/34168126PubMed
32717751Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors.Hamostaseologie2020https://conductscience.org/library/papers/32717751PubMed
32425925Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.Front Immunol2020https://conductscience.org/library/papers/32425925PubMed
32373126Suppression of FVIII-Specific Memory B Cells by Chimeric BAR Receptor-Engineered Natural Regulatory T Cells.Front Immunol2020https://conductscience.org/library/papers/32373126PubMed
32351497The Immune Response to the fVIII Gene Therapy in Preclinical Models.Front Immunol2020https://conductscience.org/library/papers/32351497PubMed
31454152The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.J Thromb Haemost2020https://conductscience.org/library/papers/31454152PubMed
30705923Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.Mol Ther Methods Clin Dev2019https://conductscience.org/library/papers/30705923PubMed
30411401Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.Eur J Haematol2019https://conductscience.org/library/papers/30411401PubMed
29392598The impact of extended half-life versus conventional factor product on hemophilia caregiver burden.Qual Life Res2018https://conductscience.org/library/papers/29392598PubMed
27445481Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.Ther Clin Risk Manag2016https://conductscience.org/library/papers/27445481PubMed
27440064Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.Oncologist2016https://conductscience.org/library/papers/27440064PubMed
27061380Gene therapy for immune tolerance induction in hemophilia with inhibitors.J Thromb Haemost2016https://conductscience.org/library/papers/27061380PubMed
26770953Immune tolerance induction in patients with severe hemophilia A with inhibitors.Blood Res2015https://conductscience.org/library/papers/26770953PubMed

See all 32 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/72276

GET https://conductscience.org/api/papers/v1/72276/cited_by?page=2